Artiva Biotherapeutics, Inc. Common Stock (ARTV) — Cash Flow-to-Debt Ratio
Artiva Biotherapeutics, Inc. Common Stock (ARTV) has a Cash Flow-to-Debt Ratio of -0.98x as of September 2025, meaning its operating cash flow of $-19.20 Million could theoretically repay -1% of its total liabilities ($19.64 Million) in one year. See Artiva Biotherapeutics, Inc. Common Stoc financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Artiva Biotherapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio (2020–2024)
Historical debt coverage capacity for Artiva Biotherapeutics, Inc. Common Stock across 5 annual periods. For the full cash flow conversion analysis, see Artiva Biotherapeutics, Inc. Common Stoc (ARTV) cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Artiva Biotherapeutics, Inc. Common Stock (2020–2024)
Year-by-year debt coverage analysis for Artiva Biotherapeutics, Inc. Common Stock. Check ARTV cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -2.40x | $-55.03 Million | $22.94 Million | ▼ -1251.1% |
| 2023 | -0.18x | $-47.43 Million | $267.13 Million | ▲ +4.4% |
| 2022 | -0.19x | $-50.83 Million | $273.75 Million | ▼ -214.0% |
| 2021 | -0.06x | $-15.30 Million | $258.78 Million | ▲ +77.8% |
| 2020 | -0.27x | $-13.54 Million | $50.80 Million | — |